Cutting stack (for visceral)

Tesamorelin is the only growth-hormone–axis compound with peer-reviewed human trial data showing significant, reproducible loss of visceral fat — the deep, metabolically active fat that resists diet and training. Across phase-3 trials, daily Tesamorelin reduced visceral adipose tissue by ~15–18% over 26 weeks versus placebo, with concurrent reduction in liver fat and no adverse effect on fasting glucose. The branded medicine Egrifta is FDA-approved for excess abdominal fat in adults with HIV-associated lipodystrophy; this approval does not apply to VCP research products. Ipamorelin is the ideal partner: a highly selective ghrelin-receptor agonist that adds a clean physiological GH pulse on top of the Tesamorelin GHRH signal — without raising cortisol, prolactin or appetite. Typically dosed nightly during cutting blocks of 8–12 weeks.